Published in PLoS One on January 24, 2012
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 2.16
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med (2016) 1.41
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog (2012) 1.34
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem (2013) 1.17
Understanding HIV latency: the road to an HIV cure. Annu Rev Med (2015) 1.07
Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol (2012) 1.07
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog (2013) 0.97
Lost in transcription: molecular mechanisms that control HIV latency. Viruses (2013) 0.96
High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol (2013) 0.94
An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. J Virol (2013) 0.94
The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. Mol Biol Int (2012) 0.93
Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology (2013) 0.92
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother (2014) 0.92
Immuno-modulatory strategies for reduction of HIV reservoir cells. J Theor Biol (2015) 0.90
Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog (2013) 0.90
A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc (2014) 0.86
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells. PLoS Pathog (2015) 0.86
Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses. J Virol (2013) 0.85
Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV. PLoS One (2013) 0.84
Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins. J Virol (2013) 0.84
HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Retrovirology (2016) 0.81
Feline immunodeficiency virus latency. Retrovirology (2013) 0.81
Translational challenges in targeting latent HIV infection and the CNS reservoir problem. J Neurovirol (2014) 0.80
Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages. Biology (Basel) (2012) 0.80
Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol Sin (2015) 0.80
HIV persistence: chemokines and their signalling pathways. Cytokine Growth Factor Rev (2012) 0.80
Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. J Immunol (2014) 0.78
Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. Retrovirology (2015) 0.78
Blimp-1, an intrinsic factor that represses HIV-1 proviral transcription in memory CD4+ T cells. J Immunol (2015) 0.77
Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus. AIDS Res Hum Retroviruses (2015) 0.77
HIV eradication: combinatorial approaches to activate latent viruses. Viruses (2014) 0.77
Bridging HIV-1 cellular latency and clinical long-term non-progressor: an interactomic view. PLoS One (2013) 0.76
Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal. EBioMedicine (2015) 0.75
Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro. PLoS One (2016) 0.75
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models. Sci Rep (2016) 0.75
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep (2017) 0.75
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol (2004) 10.60
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol (2001) 4.25
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell (2010) 3.42
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood (2008) 3.05
Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science (2001) 3.02
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe (2008) 2.81
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med (2010) 2.71
Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol (2007) 2.71
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol (2002) 2.64
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog (2007) 2.33
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis (2000) 1.96
Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods (2009) 1.91
Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol (2007) 1.74
HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology (2007) 1.61
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A (2003) 1.58
Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol (2009) 1.45
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol (2007) 1.45
An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol (2008) 1.43
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol (2011) 1.34
A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology (2006) 1.30
HIV reservoirs and latency models. Virology (2011) 1.29
Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses (2004) 1.10
Primary cell model for activation-inducible human immunodeficiency virus. J Virol (2007) 1.10
Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol (2007) 1.03
TNFR1-induced sphingomyelinase activation modulates TCR signaling by impairing store-operated Ca2+ influx. J Leukoc Biol (2005) 0.91
Primary cell models of HIV latency. Curr Opin HIV AIDS (2011) 0.87
The challenge of finding a cure for HIV infection. Science (2009) 8.41
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27
HIV vaccine research: the way forward. Science (2008) 3.86
NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol (2005) 3.50
Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell (2010) 3.42
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science (2013) 2.68
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol (2008) 2.38
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol (2004) 2.06
p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem (2004) 2.01
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 1.97
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) (2003) 1.79
Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med (2006) 1.77
Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc (2014) 1.76
Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol (2007) 1.74
Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe (2011) 1.72
Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology (2010) 1.70
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog (2007) 1.70
In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog (2007) 1.70
Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem (2006) 1.68
An integrated overview of HIV-1 latency. Cell (2013) 1.68
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Regulation of HIV-1 latency by T-cell activation. Cytokine (2007) 1.48
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol (2005) 1.42
Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem (2006) 1.42
Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J Virol (2011) 1.42
Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol (2005) 1.41
Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem (2009) 1.39
Slipping through the door: HIV entry into the nucleus. Microbes Infect (2002) 1.39
Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem (2004) 1.38
Microbial persistence and the road to drug resistance. Cell Host Microbe (2013) 1.37
Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe (2008) 1.35
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology (2004) 1.34
Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res (2008) 1.32
Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog (2011) 1.31
Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Hum Mol Genet (2011) 1.31
Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol (2004) 1.26
Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. PLoS Pathog (2013) 1.23
Human immunodeficiency virus fusion to dendritic cells declines as cells mature. J Virol (2006) 1.22
NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol (2006) 1.20
Translocation and surface expression of lipidated serogroup B capsular Polysaccharide in Neisseria meningitidis. Infect Immun (2005) 1.19
The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathog (2008) 1.18
Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem (2011) 1.18
Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev (2012) 1.14
HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology (2002) 1.14
Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol (2005) 1.13
Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol (2006) 1.12
Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol (2003) 1.11
Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem (2005) 1.10
Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect Immun (2006) 1.06
Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog (2011) 1.05
Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J Biol Chem (2003) 1.05
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Insights into the biology of HIV-1 viral protein R. DNA Cell Biol (2002) 1.02
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J Virol (2003) 1.00
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol (2010) 0.99
Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol (2011) 0.99
HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology (2010) 0.99
Seminal plasma induces global transcriptomic changes associated with cell migration, proliferation and viability in endometrial epithelial cells and stromal fibroblasts. Hum Reprod (2014) 0.97
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains. J Virol (2013) 0.96
NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS (2011) 0.95
Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology (2007) 0.94
Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol (2010) 0.93
APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J Biol Chem (2005) 0.93
Assessing acetylation of NF-kappaB. Methods (2005) 0.92
A seminal finding for understanding HIV transmission. Cell (2007) 0.92
Host factors regulating post-integration latency of HIV. Trends Microbiol (2005) 0.90
Measuring HIV fusion mediated by envelopes from primary viral isolates. Methods (2010) 0.88
Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J Biol Chem (2010) 0.86
Protecting APOBEC3G: a potential new target for HIV drug discovery. Curr Opin Investig Drugs (2005) 0.85
Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication. J Virol (2008) 0.84
How resting T cells deMURR HIV infection. Nat Immunol (2004) 0.84
Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J Virol (2013) 0.84
Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV. PLoS One (2013) 0.84
Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Retrovirology (2009) 0.84
The Vgamma2/Vdelta2 T-cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vgamma2/Jgamma1.2 subset. Immunology (2005) 0.83
Innate-like gammadelta T cell responses to mycobacterium Bacille Calmette-Guerin using the public V gamma 2 repertoire in Macaca fascicularis. Tuberculosis (Edinb) (2007) 0.81
Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. J Virol (2012) 0.79